Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene.
Nucleosides Nucleotides Nucleic Acids
; 27(6): 692-8, 2008 Jun.
Article
en En
| MEDLINE
| ID: mdl-18600527
5-Fluorouracil (5FU) and capecitabine are two of the most frequently prescribed chemotherapeutic drugs for the treatment of patients with cancer. Administration of test doses of 5FU to eight patients heterozygous for the IVS14+1G > A mutation and five control patients showed that the AUC and clearance were weak parameters with respect to the identification of patients with a DPD deficiency. However, highly significant differences were observed for the terminal half life of 5FU between DPD patients and controls. Thus, a DPD deficiency could be predicted from 5FU blood concentrations measured after the administration of a test dose of 5FU.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Dihidrouracilo Deshidrogenasa (NADP)
/
Deficiencia de Dihidropirimidina Deshidrogenasa
/
Fluorouracilo
/
Heterocigoto
/
Mutación
/
Antineoplásicos
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Nucleosides Nucleotides Nucleic Acids
Asunto de la revista:
BIOQUIMICA
Año:
2008
Tipo del documento:
Article
País de afiliación:
Países Bajos
Pais de publicación:
Estados Unidos